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MaOBJECTIVES This study aimed to assess the incremental prognostic value of global circumferential strain (GCS), as
measured using cardiac magnetic resonance (CMR) tagging, in addition to baseline clinical characteristics, left ventricular
ejection fraction (LVEF), and late gadolinium enhancement (LGE), in the prediction of major adverse cardiovascular
events (MACE) in an unselected cohort of patients.
BACKGROUND LVEF is a powerful predictor of mortality and is used for guiding treatment decisions. It is, however,
subject to limitations. The value of GCS measured by CMR tagging in patients with suspected cardiac disease has not
been fully explored despite its being considered as the gold standard noninvasive method of assessment of LV
deformation.
METHODS We prospectively evaluated data from 539 consecutive patients referred for CMR who underwent a CMR
protocol that included cine imaging, tagging, and LGE. The primary endpoint was the prevalence of MACE, deﬁned
as a composite of all-cause mortality, heart failure–related hospitalization, and aborted sudden cardiac death.
RESULTS MACE occurred in 62 of 539 patients (11.5%) over a mean follow-up period of 2.2 years. History of ischemic
heart disease (IHD) and beta-blocker use were both signiﬁcant clinical predictors of adverse outcomes. All 3 CMR
parameters were signiﬁcant multivariate predictors of the primary outcome when added to signiﬁcant clinical predictors
(LVEF, hazard ratio [HR]: 0.96 [95% conﬁdence interval [CI]: 0.94 to 0.99; p ¼ 0.005]; presence of LGE, HR: 2.07 [95%
CI: 1.03 to 4.14; p ¼ 0.04]; GCS, HR: 1.11 [95% CI: 1.02 to 1.21; p ¼ 0.041]). Global chi-square increased signiﬁcantly with
the addition of both LGE and GCS. Both the presence of LGE and reduced GCS had independent prognostic value in the
overall cohort. Patients with LVEF $35% but LGE present and reduced GCS had a poor outcome similar to that in those
with LVEF <35%.
CONCLUSIONS We found, in a large-scale cohort of patients, that GCS, in addition to clinical variables, LVEF, and LGE,
had incremental independent prognostic value. This measure could provide further risk stratiﬁcation, especially in pa-
tients with mild LV impairment. (J Am Coll Cardiol Img 2015;8:540–9) © 2015 by the American College of Cardiology
Foundation.T he assessment of myocardial function byleft ventricular ejection fraction (LVEF) hasan important role in the evaluation and
management of patients in cardiology, providing sig-
niﬁcant prognostic information and guidingm the *British Heart Foundation Glasgow Cardiovascular Research Centr
iversity of Glasgow, Glasgow, United Kingdom; and the yHarrington Hea
dical Center, Case Western Reserve University, Cleveland, Ohio. The au
evant to the contents of this paper to disclose.
nuscript received November 7, 2014; revised manuscript received Februatreatment decisions (1–3). Although myocardial func-
tion is commonly evaluated using echocardiography,
cardiac magnetic resonance (CMR) is becoming
increasingly utilized. CMR is currently recognized as
the gold standard noninvasive strategy for thee, Institute of Cardiovascular and Medical Sciences,
rt and Vascular Institute, University Hospitals Case
thors have reported that they have no relationships
ry 11, 2015, accepted February 12, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
GCS = global circumferential
strain
IHD = ischemic heart disease
LGE = late gadolinium
enhancement
LVEF = left ventricular
ejection fraction
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541assessment of LVEF due to its advantages of
providing unobstructed views of the heart in any
plane and increased reproducibility (4).
A further advantage of CMR is tissue characteriza-
tion by late gadolinium enhancement (LGE) imaging.
The acquisition of images obtained 10 min after
intravenous gadolinium contrast injection allows for
the visualization of myocardial ﬁbrosis. The presence
of ﬁbrosis is seen in numerous conditions and has
also been shown to have signiﬁcant prognostic value
independent of LVEF (5–7).SEE PAGE 550
LVSD = left ventricular
systolic dysfunction
MACE = major adverse
cardiovascular events
SCD = sudden cardiac deathDespite LVEF assessment by CMR being well vali-
dated, LVEF can be insensitive for the assessment of
myocardial contractility. LVEF is dependent on other
factors, including preload and afterload, and as
such does not always identify subtle but important
changes in LV systolic function (8). Early changes in
myocardial contractility that are not identiﬁed by a
decline in LVEF may still have an important clinical
impact. The assessment of myocardial contractility,
most commonly reported using strain as a measure
of deformation, can be carried out using tagging se-
quences during CMR (9). This technique is regarded
as the gold standard noninvasive strategy for defor-
mation imaging. The assessment of global circum-
ferential strain (GCS) using tagging has been shown to
identify myocardial dysfunction in numerous condi-
tions independent of LVEF. Recently, GCS has been
shown to be an independent prognostic indicator in
both asymptomatic patients and those with heart
failure (10,11).
As yet, no study has assessed the prognostic value
of GCS, in addition to LVEF, LGE, and in a combined
CMR protocol. The aim of this study was to explore
the prognostic value of these parameters in addition
to baseline clinical risk factors in the prediction of
major adverse cardiovascular events (MACE) in an
unselected cohort of patients with suspected cardiac
disease referred for clinical assessment.
METHODS
PATIENT SELECTION. Over the inclusion period, we
prospectively evaluated data from 570 consecutive
patients referred to the Golden Jubilee National
Hospital, Clydebank, Glasgow, United Kingdom, for
clinically indicated CMR and without contraindica-
tions to gadolinium contrast. Eligible patients were
able to undergo the complete CMR protocol. Clinical
management of the patients was left to the discretion
of the referring physician. Baseline characteristics
were obtained at the time of referral using eachpatient’s electronic medical record. The
study was approved by the local ethics
committee.
CMR PROTOCOL. All patients underwent
scanning using a 1.5-T magnetic resonance
imaging scanner (Avanto, Siemens, Erlangen,
Germany) and underwent a standardized
CMR protocol. Detailed imaging-acquisition
methods have been previously described (7).
Brieﬂy, after initial localizers, cine imaging
was performed using a steady-state free pre-
cession technique in 3 long-axis views (2-, 3-,
and 4-chamber) and a series of short-axis
slices (8 to 10, typically) covering the entire
left ventricle, from base to apex (imaging
parameters: repetition time/echo time/ﬂip
angle, 1.4 ms/3.5 ms/50; spatial resolution, 1.7 
2 mm; slice thickness, 8 mm).
Tagged CMR images were acquired using a spatial
modulation of magnetization sequence in 3 short-axis
slices selected to represent the basal, mid, and apical
levels of the left ventricle (12). Grid tags were applied
at the start of the electrocardiograph R-wave, and
gradient echo cine images were acquired to follow
myocardial motion using the tags. Care was taken to
ensure adequate diastolic phase covering in patients
with arrhythmia. Imaging parameters for tagging
were as follows: repetition time, 4.1 ms; echo time,
3.9 ms; ﬂip angle, 14; slice thickness, 6 mm; ﬁeld of
view, 380 mm; grid distance, 5 mm. The number of
cardiac phases was dependent on the patient’s heart
rate. Mean temporal resolution was 32  4 ms.
For LGE imaging, intravenous gadolinium contrast
was injected (total dose of gadolinium–diethylene-
triamine penta-acetic acid, 0.15 mmol/kg). Ten
minutes later, images were acquired using a phase-
sensitive inversion recovery technique (13).
CMR ANALYSIS. LVEF was calculated from the
short-axis cine images with post-processing using
proprietary software (Argus; Siemens, Erlangen,
Germany). Endocardial contours were drawn at both
end-diastole (deﬁned by the software) and end-
systole (manually deﬁned as the image with the
smallest area of myocardium). This technique was
repeated for each short-axis slice, and LVEF was
calculated by the software using the summation-of-
discs method.
Tagged CMR images were analyzed using the har-
monic phase method (HARP version 5.03, Diagnosoft,
Durham, North Carolina). Endocardial and epicardial
borders were drawn for each slice, allowing for
tracking of each tag throughout the cardiac cycle (14).
The tags were then manually adjusted to ensure
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542accurate tracking. Circumferential (Eulerian) strain
was calculated for each slice. GCS was calculated as
the peak circumferential strain, using the mean of the
3 slices. As GCS is a measure of circumferential
shortening from baseline, it is typically a negative
value. Greater amounts of circumferential shortening
are indicated by a more negative value.
LGE images were also analyzed using Argus as
previously described (7). LGE was considered to be
present in any areas with a signal intensity 5 SD above
that of normal myocardium. If LGE was present,
the percentage of myocardial LGE was quantiﬁed
by calculating the area of LGE each slice. The total
percentage of myocardial LGE was calculated as
(13): (total area of myocardial LGE/total area of
myocardium)  100.
Examples of the CMR protocol are shown in
Figures 1 and 2.
FOLLOW-UP. The primary endpoint in this study was
the prevalence of MACE, deﬁned as a composite of
all-cause mortality, heart failure–related hospitaliza-
tion, and aborted sudden cardiac death (SCD). All
patients were followed up using a computed record-FIGURE 1 Example of the CMR Protocol in a Healthy Patient
Cine imaging in diastole (A) and systole (B), tagging in diastole (C) and
basal slice, blue ¼ midslice, green ¼ apical slice) in a patient with an LV
circumferential strain; LGE ¼ late gadolinium enhancement; LVEF ¼ leftlinkage system, which allowed us to identify sur-
vival status and hospital admissions using access to
patients’ records (7). In cases in which electronic re-
cords were not up to date, the primary care practi-
tioner was contacted to ensure adequate follow-up
status. Events were adjudicated by an independent
observer blinded to the results (N.T.).
STATISTICAL ANALYSIS. All statistical analyses were
carried out using SPSS version 22.0 (IBM, Armonk,
New York). Continuous variables are reported as
mean  SD; categorical data, as n (%). Comparisons
between continuous variables were carried out using
a 2-tailed Student t test; categorical variables, the chi-
square test. Correlations between CMR parameters
were assessed using the Pearson correlation coefﬁ-
cient. Outcomes analysis was conducted using a
Cox proportional hazards model, and time-to-event
curves were drawn using the Kaplan-Meier method.
All variables were evaluated using univariate Cox
regression analysis to ascertain their prognostic
power in predicting the primary outcome. Hazard
ratios (HRs) (95% conﬁdence intervals [CIs]) and chi-
square values were obtained. All signiﬁcant clinicalsystole (D), absence of LGE (E) and normal GCS (–16.4%) (F) (pink ¼
EF of 62%. CMR ¼ cardiac magnetic resonance; GCS ¼ global
ventricular ejection fraction.
FIGURE 2 Example of the CMR Protocol in a Patient With Dilated Cardiomyopathy
Cine imaging in diastole (A) and systole (B), tagging in diastole (C) and systole (D), midwall LGE (E) and reduced GCS (–4.6%) (F) (pink ¼ basal
slice, blue ¼ midslice, green ¼ apical slice) in a patient with an LVEF of 28%. Abbreviations as in Figure 1.
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543univariate predictors (p < 0.10) were then entered
into a multivariate Cox model to identify signiﬁcant
multivariate clinical predictors. To evaluate the in-
cremental prognostic value of CMR, signiﬁcant uni-
variate CMR predictors (p < 0.05) were then added to
the signiﬁcant multivariate clinical predictors, with
further multivariate models using each CMR param-
eter singly created. Optimal cutoff points for LVEF,
GCS, and LGEwere calculated using receiver-operating
characteristic (ROC) curves, as well as division of
the groups into tertiles as necessary. The chi-square
value of each model was subsequently calculated.
This process was then repeated in patients without
severe LV systolic dysfunction (LVSD) ($35%). Repro-
ducibility was assessed using the Pearson correlation
coefﬁcient and the intraclass coefﬁcient.
RESULTS
BASELINE CHARACTERISTICS. In total, 539 patients
were included in the ﬁnal analysis. Of the 31 patients
excluded, 12 had arrhythmias that impaired scan
quality (e.g., uncontrolled atrial ﬁbrillation), 11patients had inadequate image quality due to poor
breath-holding ability, and 8 were unable to undergo
LGE imaging due to renal impairment. The baseline
clinical characteristics of the 539 patients are shown
in Table 1. The mean age of the cohort was 48.1  15.4
years; 63.6% were male. The majority of patients did
not have any clinical risk factors. The reasons for
referral for CMR are shown in Table 2. The majority
of patients (56.8%) were referred for further clinical
risk stratiﬁcation of suspected heart failure (accurate
LV function assessment and the presence of LGE).
Baseline CMR characteristics are shown in Table 3.
Mean LVEF measured by CMR was 55.9  14.1% and
mean GCS was –13.4  4.6%. A total of 164 patients
had LGE present (30.4%). The mean volume of LGE
was 4.1  10.4%. There was a strong correlation be-
tween all 3 parameters (correlation between LVEF
and LGE percentage, r ¼ –0.43; between LVEF and
GCS, r ¼ –0.58; between GCS and LGE percentage,
r ¼ 0.33; all, p < 0.001). Mean acquisition time of
tagged CMR was 104  22 s (1.7  0.37 min); mean
time of post-processing analysis of tagged CMR was
3.6  0.7 min.
TABLE 1 Baseline Clinical Characteristics (N ¼ 539)
Age, yrs 48.1  15.4
Male 343 (63.6)
Caucasian 504 (93.5)
Ischemic heart disease 61 (11.3)
Diabetes mellitus 53 (9.8)
Hypertension 77 (14.3)
Smoker 58 (10.8)
ACE inhibitor use 225 (41.7)
Beta-blocker use 223 (41.4)
Statin use 140 (26.0)
Aspirin use 159 (29.5)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme.
TABLE 3 Baseline CMR Characteristics (N ¼ 539)
LVEF, % 55.9  14.1
LVEDVi, ml/m2 99.7  38.9
LVESVi, ml/m2 51.2  39.2
LV mass index, g/m2 88.1  28.7
GCS, % –13.4  4.6
LGE present 164 (30.4)
LGE, % 4.1  10.4
Values are mean  SD or n (%).
GCS ¼ global circumferential strain; LGE ¼ late gadolinium enhancement;
LV ¼ left ventricular; LVEDVi ¼ left ventricular end-diastolic volume index;
LVEF ¼ left ventricular ejection fraction; LVESVi ¼ left ventricular end-systolic
volume index; other abbreviation as in Table 2.
TABLE 4 Post-CMR Diagnoses of Patients Suffering the
Primary Outcome
Total Number
of Patients
Number of Patients
Suffering Primary
Outcome
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544PRIMARY OUTCOME. The mean follow-up duration
was 2.2  1.2 years. MACE occurred in 62 of 539 pa-
tients (11.5%). The post-CMR diagnoses in patients
with MACE are given in Table 4. There were 20 deaths
(16 cardiac related, 4 noncardiac related), 30 admis-
sions for heart failure, and 12 aborted SCDs. Age;
history of IHD; the presence of diabetes; smoking
habit; and treatment with angiotensin-converting
enzyme inhibitors, beta-blockers, aspirin, and/or
statins were all signiﬁcant univariate clinical pre-
dictors of the primary outcome (Table 5). On multi-
variate analysis of signiﬁcant clinical predictors, only
a history of IHD (HR: 3.58; 95% CI: 1.77 to 7.22;
p < 0.001) and beta-blocker use (HR: 2.29; 95% CI: 1.01
to 5.20; p ¼ 0.048) remained signiﬁcant predictors of
the primary outcome (Table 5).
INCREMENTAL PROGNOSTIC VALUE OF CMR
PARAMETERS. All 3 CMR parameters were signiﬁcant
univariate predictors of the primary outcome (LVEF,
HR: 0.92 [95% CI: 0.91 to 0.94; p < 0.001]; presence of
LGE, HR: 5.47 [95% CI: 3.16 to 9.48; p < 0.001]; GCS,
HR: 1.21 [95% CI: 1.16 to 1.27; p < 0.001]) (Figure 3).
When individually added to signiﬁcant clinical pre-
dictors on multivariate analysis, all 3 CMR parameters
remained signiﬁcant (Table 6). In the ﬁnal multivar-
iate model, all 3 CMR parameters remained signiﬁcantTABLE 2 Reasons for Referral for CMR Assessment (N ¼ 539)
Presumed dilated nonischemic cardiomyopathy—
risk stratiﬁcation
199 (36.9)
Presumed ischemic cardiomyopathy—risk stratiﬁcation 107 (19.9)
Ventricular arrhythmia 75 (13.9)
Presumed myocarditis 64 (11.9)
Left ventricular hypertrophy—characterization 59 (10.9)
Aortic disease 35 (6.5)
Values are n (%).
CMR ¼ cardiac magnetic resonance.predictors of the primary outcome (LVEF, HR: 0.96
[95% CI: 0.94 to 0.99; p ¼ 0.005]; presence of LGE,
HR: 2.07 [95% CI: 1.03 to 4.14; p ¼ 0.040]; GCS, HR:
1.11 [95% CI: 1.02 to 1.21; p ¼ 0.041]). The addition of
both LGE and GCS had incremental prognostic value
when added to clinical predictors and LVEF.
All 3 CMR parameters had reasonable accuracy in
the prediction of AEs. The area under the ROC curve
for LVEF was 0.834; for LGE, 0.699; and GCS, 0.820
(all, p < 0.001).
In patients with nonischemic cardiomyopathy,
both the presence of LGE (HR: 2.65; 95% CI: 1.18 to
5.95; p ¼ 0.018) and GCS (HR: 1.13; 95% CI: 1.01 to 1.27;
p ¼ 0.031) remained signiﬁcant multivariate pre-
dictors of adverse outcome.
CMR PREDICTORS IN PATIENTS WITH ISCHEMIC
CARDIOMYOPATHY OR PRIOR MYOCARDIAL
INFARCTION. There were 90 patients with a CMR-
conﬁrmed diagnosis of ischemic cardiomyopathy or
evidence of a prior myocardial infarction, 26 of whom
experienced MACE. Both LVEF (HR: 0.95; 95% CI:
0.92 to 0.98; p ¼ 0.001) and GCS (HR: 1.18; 95% CI:Ischemic cardiomyopathy 90 26 (28.9)
Dilated cardiomyopathy 159 16 (10.1)
Valvular heart disease 26 4 (15.4)
Amyloidosis 3 3 (100.0)
Myocarditis 37 3 (8.1)
Left ventricular noncompaction 4 2 (50.0)
Fabry disease 2 1 (50.0)
Hypertensive heart disease 32 1 (3.1)
Constrictive pericarditis 2 1 (50.0)
No abnormality 184 5 (2.7)
Values are n or n (%).
Abbreviation as in Table 2.
TABLE 5 Clinical Predictors of the Primary Outcome (N ¼ 539)
Univariate Analysis Multivariate Analysis
HR (95% CI) p Value HR (95% CI) p Value
Age 1.04 (1.02–1.06) <0.001 1.02 (1.00–1.05) 0.10
Male 1.68 (0.95–2.97) 0.08 – –
Ischemic heart disease 6.77 (3.80–12.04) <0.001 3.58 (1.77–7.22) <0.001
Diabetes mellitus 2.02 (1.01–4.05) 0.047 0.83 (0.40–1.73) 0.61
Hypertension 1.43 (0.72–2.86) 0.31
Smoker 2.21 (1.14–4.32) 0.02 1.62 (0.82–3.21) 0.17
ACE inhibitor use 4.76 (2.54–8.92) <0.001 1.45 (0.66–3.17) 0.36
Beta-blocker use 5.26 (2.76–10.02) <0.001 2.29 (1.01–5.20) 0.048
Statin use 2.86 (1.67–4.91) <0.001 0.76 (0.36–1.62) 0.52
Aspirin use 3.53 (2.04–6.10) <0.001 1.31 (0.57–3.00) 0.48
ACE ¼ angiotensin-converting enzyme; CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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5451.05 to 1.32; p ¼ 0.007) were signiﬁcant univariate
CMR predictors of the primary outcome in this group.
PATIENTS WITHOUT SEVERELY IMPAIRED LV
FUNCTION. In total, there were 474 patients with
LVEF $35%, of whom 35 experienced the primary
outcome (7.4%) (11 deaths, 14 admissions for heart
failure, and 10 aborted SCDs). Using ROC analysis,
optimal cutoffs for LVEF and GCS were 50.2% and
–12.1%, respectively. In this group, both the presence
of LGE (HR: 3.88; 95% CI: 1.86 to 8.09; p < 0.001)
and GCS (HR: 1.09; 95% CI: 1.00 to 1.19; p ¼ 0.046)
remained signiﬁcant multivariate predictors of the
primary outcome when added to LVEF (HR: 0.93; 95%
CI: 0.90 to 0.97; p ¼ 0.001) (Figure 4).
Patients with LVEF $35% but with LGE present and
GCS $12.1% had a poor outcome similar to that in
patients with LVEF <35%, whereas patients with
LVEF $35%, no LGE, and GCS <–12.1% had a much
better outcome (Figure 5).
REPRODUCIBILITY OF GCS MEASUREMENTS USING
TAGGING. The reproducibility of GCS measurements
was assessed in 30 patients. There was excellent
intraobserver variability (r ¼ 0.96; p < 0.01) and
interobserver agreement (r ¼ 0.94; p < 0.01). The
intraclass correlation coefﬁcient for intraobserver
agreement was 0.96 (95% CI: 0.93 to 0.98; p < 0.001)
and interobserver agreement was 0.95 (95% CI: 0.88
to 0.98; p < 0.001).FIGURE 3 Survival Curves for the Primary Outcome
Kaplan-Meier curves stratiﬁed by LVEF (A), the presence of LGE (B) and
ventricular ejection fraction.DISCUSSION
For the ﬁrst time in a large-scale, prospectively
evaluated cohort of unselected patients, we have
shown that the assessment of GCS using CMR tagging
has independent and incremental value in the pre-
diction of MACE when added to the clinical predictors
LVEF and LGE as a part of a routine CMR protocol.
Importantly, this incremental predictive value of GCS
held true in the absence of signiﬁcant LVSD, extend-
ing its applicability.GCS (C). GCS ¼ global circumferential strain; LGE ¼ late gadolinium enhancement; LVEF ¼ left
TABLE 6 Multivariate Analysis Including CMR Parameters (N ¼ 539)
Clinical þ LVEF* Clinical þ LGE† Clinical þ GCS‡ Clinical þ LVEF þ LGE§ Clinical þ LVEF þ LGE þ GCSk
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
IHD 3.70 (2.04–6.69) <0.001 2.84 (1.53–5.31) 0.001 3.95 (2.17–7.17) <0.001 2.70 (1.41–5.14) 0.003 2.71 (1.41–5.21) 0.003
Beta-blocker use 1.58 (0.74–3.34) 0.23 2.93 (1.47–5.84) 0.002 1.96 (0.95–4.05) 0.07 1.62 (0.77–3.42) 0.20 1.45 (0.68–3.08) 0.34
LVEF (%) 0.94 (0.92–0.96) <0.001 – – – – 0.95 (0.93–0.97) <0.001 0.96 (0.94–0.99) 0.005
LGE present – – 3.46 (1.82–6.59) <0.001 – – 2.14 (1.06–4.33) 0.027 2.07 (1.03–4.14) 0.040
GCS (%) – – – – 1.22 (1.14–1.31) <0.001 – – 1.11 (1.02–1.21) 0.041
Chi-square: *126.46; †94.12; ‡105.26; §130.07 (p < 0.05 vs. Clinical þ LVEF model); and k133.60 (p < 0.05 vs. Clinical þ LVEF model).
IHD ¼ ischemic heart disease; GCS ¼ global circumferential strain; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction; other abbreviations as in Tables 2 and 5.
FIGURE 4 Surviva
Kaplan-Meier curves
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546LVEF has been shown to be a strong predictor of
adverse outcomes (1,15). The presence of severe
LVSD, deﬁned by an LVEF <35%, is a marker of poor
prognosis and is commonly used for guiding treat-
ment decisions regarding the use of therapies such as
implantable cardioverter-deﬁbrillators and cardiac
resynchronization therapy (2,3). Patients with
reduced LVEF (and/or previous myocardial infarc-
tion) are also commonly prescribed beta-blockers,
which are known to improve LVSD, thus explaining
the increased hazard ratio in this study in patients
prescribed this class of drugs (16,17). Despite these
factors, the use of LVEF alone is subject to somel Curves for the Primary Outcome in Patients With an LVEF of $35%
stratiﬁed by the presence of LGE (A) and the optimal cutoff for GCS (B). Ablimitations. Firstly, it is known that a strict cutoff on
the basis of LVEF may still miss patients at higher
risk, as patients with LVEF >35% can still have ad-
missions for heart failure and cardiac death (18–20).
Secondly, LVEF is not a measure purely of contrac-
tility, as it is affected by volumes, loading conditions,
heart rate, and valvular function, among other fac-
tors, meaning that patients with a preserved or mildly
reduced LVEF may still have an adverse prognosis
(21), whereas some healthy patients may actually
have reduced LVEF (22). These limitations have led to
the search for other parameters that may improve risk
stratiﬁcation.breviations as in Figure 3.
FIGURE 5 Survival Curves for the Primary Outcome, Stratiﬁed by CMR Variables
Kaplan-Meier curves stratiﬁed by LVEF, and the presence of LGE and GCS, showing that
patients with an LVEF of $35% but with an LGE present and a GCS of $–12.1% had an
outcome as poor as that in patients with an LVEF of <35%. GCS ¼ global circumferential
strain; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction.
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547LGE has emerged as a powerful predictor of
adverse outcomes in patients with both reduced and
preserved LVEF (23–26). Its absence may provide
assurance to clinicians about patients who might
already be at high risk for MACE (7). The presence of
LGE signiﬁes myocardial ﬁbrosis, which, in addition
to reducing overall myocardial contractility, might
represent a substrate for ventricular arrhythmias that
might lead to SCD (27–29). This study adds to the
increasing evidence suggesting that the presence of
LGE is an adverse prognostic indicator not only in
conventionally high-risk patients (LVEF <35%) but
also in those who might be thought to have a reduced
risk (LVEF $35%).
The measurement of circumferential strain may
aim to resolve some of the problems associated with
LVEF. GCS is perhaps a more sensitive measure of
myocardial contractile function (9). Strain measured
using echocardiography has been shown to be an in-
dependent marker of adverse prognosis that adds
incremental value to LVEF (11). However, although
CMR tagging is accepted as the gold standard nonin-
vasive strategy for the assessment of strain, only one
study has evaluated the prognostic value of tagging.
In the MESA (Multi-Ethnic Study of Atherosclerosis)
cohort, Choi et al. (10) evaluated data from 1,768
asymptomatic patients who underwent CMR tagging.
The authors found that GCS provided incremental
prognostic value when added to baseline clinical
variables and LVEF, including in patients with pre-
served LVEF.
Our study, on one hand, parallels the results of
Choi et al. (10), and on the other extends its obser-
vations to patients with suspected cardiac disease,
underscoring the additional clinical value of CMR
tagging. Similar to Choi et al. (10), we also found that
GCS was an independent predictor of MACE in a large-
scale, unselected cohort of patients undergoing CMR
examination. In addition, we found that an incre-
mental beneﬁt of GCS when the presence of LGE was
included. This incremental value provides informa-
tion to suggest that the addition of tagging to routine
CMR protocols that already includes LVEF and LGE
assessment may have some clinical beneﬁt.
We hypothesize that the incremental beneﬁt of
GCS may be due to 2 reasons. First, strain is a more
sensitive measure of contractile dysfunction than
LVEF (8,30). Indeed, GCS is the major contributor
to LV stroke volume (8). Second, LGE often does
not identify diffuse myocardial ﬁbrosis due to the
need for identifying areas of “nulled” healthy myo-
cardium (31). We postulate that the assessment
of GCS may identify areas of reduced contractility
caused by diffuse ﬁbrosis not picked up by LGE(which is a marker of focal ﬁbrosis), although further
study is needed for conﬁrming or refuting this
hypothesis (32). Additionally, T1 mapping techniques
are becoming increasingly utilized for the assess-
ment of diffuse myocardial ﬁbrosis not identiﬁed by
LGE and have been shown to correlate well with GCS
(33). These 2 reasons may provide some explanation
for the incremental prognostic value of GCS in patients
with moderate and preserved LV function. Interest-
ingly, the presence of LGE was a stronger predictor of
outcome in this group, which might have implications
on the use of deﬁbrillator therapies in this group,
as it might suggest that the more common cause
of adverse outcomes in this group is ventricular
arrhythmia rather than pump failure. Our results
suggest that perhaps this might have been the case.
Intriguingly, there appears to be a trend toward
worse outcomes over time in the group of patients
with LVEF >35% but either LGE present or reduced
GCS. We speculate that the presence of LGE or
reduced strain might be earlier indicators of adverse
outcome than LVEF, and a larger-scale study with a
longer follow-up period may identify the possible
mechanism of this.
We found that the addition of CMR tagging did not
add too much time to our standard CMR protocol. Ul-
timately, the assessment of GCS could be incorporated
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
additional assessment of myocardial deformation
by using tagged cardiac magnetic resonance can
provide incremental prognostic value over and above
left ventricular ejection fraction and the presence
of late gadolinium enhancement in a variety of
conditions.
TRANSLATIONAL OUTLOOK: Larger, multicenter
trials are needed to identify the impact of tagging
in speciﬁc conditions in order to investigate its
clinical utility and potentially identify new therapeutic
targets.
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548into routine CMR examinations and provides incre-
mental prognostic value in addition to LVEF and
LGE. The identiﬁcation of patients with LVEF $35%
but reduced GCS and LGE may identify a group
that could beneﬁt from more advanced therapies.
Although current guidelines recommend the use of
advanced heart failure therapies and devices in
patients with LVEF <35%, it is increasingly accepted
that most SCDs actually occur in patients with
LVEF $35% (20). Nonetheless, it is important to re-
cognize that in this study, LVEF was still by far the
strongest predictor of outcome, and so both LGE
and GCS should be used as additional, rather than
replacement, diagnostic tools.
STUDY LIMITATIONS. This study may have an
element of referral bias. CMR is not yet a routine part
of clinical care (for most conditions), and so we may
have only been referred patients about whom the
clinician wished to have had further information.
Nonetheless, we feel that by having included con-
secutive patients with very few exclusions, we were
able to obtain generalizable data.
The inclusion of all-comers in our study also
added a potential limitation in terms of analysis of
our results, as the effects of different treatments in
different diseases and their effects on CMR parame-
ters were not analyzed. A larger-scale study that al-
lows for subgroup analyses, or several studies in
cohorts of patients with one pathology (e.g., ischemic
cardiomyopathy), would be required. We do believe,
though, that the mixed cohort in this study does
provide some advantages, however, and perhaps al-
lows for a level of generalizability to the practicing
clinician.
We assessed only GCS in this study; to keep scan
times to a minimum, we did not obtain long-axis
views for the assessment of global longitudinal
strain in this cohort. However, global longitudinal
strain has been shown to be a strong echocardio-
graphic predictor of outcome (34). Additionally, wedid not assess strain rate or diastolic parameters
in this cohort, which might also have prognostic
value.
CONCLUSIONS
The assessment of GCS by CMR tagging provides
incremental prognostic value for the prediction of
MACEwhen added to baseline clinical variables, LVEF,
and LGE in a routine CMR protocol in patients with
and without severe LV systolic dysfunction. The
assessment of myocardial strain may be a useful
additional parameter to include in CMR-scanning
protocols and could be used for further risk stratiﬁca-
tion in patients with mildly impaired LV systolic
function.
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